Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
prnewswire.com
news
2022-06-02 12:00:00

SAN DIEGO, June 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc.Â (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Amin Kamel, Ph.D., as Vice President, DMPK. In his role, Dr. Kamel will support clinical development, in particular advancement of the Company's lead candidate, RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD).
